AnaptysBio (ANAB) CEO Daniel Faga Receives 53,334-Share PSU Award

What Happened Daniel Faga, President, CEO and a director of AnaptysBio, received 53,334 performance-based restricted stock units (PSUs) on March 12, 2026. The Form 4 reports the award as a derivative acquisition at $0.00 per share (no cash paid). The PSUs were certified as earned by the Compensation Committee and are reported as an award/grant rather than an open-market purchase or sale.

Key Details

• Transaction date: March 12, 2026; Filing date (Form 4): August 7, 2026 (filing delayed relative to transaction date).
• Transaction type: Award/Grant (derivative) — 53,334 PSUs acquired at $0.00.
• Reported value on Form 4: $0.00 (reflects award reporting; not an open-market purchase).
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes: F1 — PSUs were earned as certified by the Compensation Committee; F2 — each PSU converts to one share of common stock; F3 — PSUs vest and settle over two years (50% on Mar 12, 2027 and 50% on Mar 12, 2028), subject to continued service.

Context These PSUs are a compensation award that convert into common shares as they vest; they are not an immediate purchase or sale of stock. Because vesting is staggered (half in 2027, half in 2028) and subject to continued service, the economic benefit to the insider depends on future vesting and the stock price at that time. Note the Form 4 was filed several months after the March 12, 2026 grant date, which affects timeliness of disclosure but not the underlying award.